BRIEF published on 10/07/2026 at 08:26, 22 days 12 hours ago Valerio Therapeutics: Review of the First Half of 2026 Financial Results Valerio Therapeutics Etherna Acquisition Abivax Collaboration InVimmune
BRIEF published on 08/24/2026 at 08:05, 2 months 5 days ago Valerio Therapeutics Acquires Etherna and Secures Financing Valerio Therapeutics Etherna Immunotherapies RNA Therapeutics Acquisition PIPE Financing Biotech Integration
PRESS RELEASE published on 08/24/2026 at 08:00, 2 months 5 days ago Inside Information / Operations of the issuer (acquisitions, sales...) Valerio Therapeutics announces acquisition of Etherna Immunotherapies for €30 million enterprise value and €40.25 million PIPE financing. Shareholder approval secured Acquisition Valerio Therapeutics RNA Therapeutics Etherna Immunotherapies PIPE Financing
BRIEF published on 07/16/2026 at 09:12, 3 months 13 days ago Valerio Therapeutics and Abivax join forces for innovative therapies Abivax Collaboration Inflammatory Diseases Valerio Therapeutics RNA Therapies
BRIEF published on 07/16/2026 at 09:12, 3 months 13 days ago Valerio Therapeutics Partners with Abivax for RNA Therapeutics Development Biotechnology Valerio Therapeutics Pipelines RNA Therapeutics Abivax Collaboration
PRESS RELEASE published on 07/16/2026 at 09:07, 3 months 13 days ago Inside Information / Other news releases Valerio Therapeutics partners with Abivax for global collaboration, providing pipeline update on RNA therapeutics. Initial payment up to €2.4 million Abivax Collaboration Valerio Therapeutics Pipeline Update RNA Therapeutics
BRIEF published on 07/01/2026 at 09:27, 3 months 28 days ago Valerio Therapeutics Proposes to Acquire Etherna Immunotherapies Biotechnology Valerio Therapeutics Acquisition Deal RNA Medicines Etherna Immunotherapies
BRIEF published on 07/01/2026 at 09:27, 3 months 28 days ago Valerio Therapeutics is preparing to acquire Etherna Immunotherapies Valerio Therapeutics Biotechnology Investment Etherna Acquisition RNA Drugs Mergers Of Companies
PRESS RELEASE published on 07/01/2026 at 09:22, 3 months 28 days ago Inside Information / Other news releases Valerio Therapeutics announces binding offer to acquire Etherna Immunotherapies, creating global leader in targeted RNA medicines. Strategic move unlocked by leading investors Acquisition Valerio Therapeutics RNA Medicines Targeted Delivery Etherna Immunotherapies
BRIEF published on 06/16/2026 at 19:48, 4 months 13 days ago Valerio Therapeutics Appoints New CEO and Confirms AGM Resolutions Biotechnology CEO Transition Valerio Therapeutics Gilles Besin RNA Medicines
Published on 10/29/2026 at 18:30, 2 hours 45 minutes ago Kidoz Inc. Appoints Derek Sentner as Chief Revenue Officer
Published on 10/29/2026 at 16:05, 5 hours 10 minutes ago SouthGobi Announces Date of Special Meeting of Shareholders and The Record Date
Published on 10/29/2026 at 13:31, 7 hours 44 minutes ago First Breach Advances Ammunition and Drone Manufacturing Expansion as U.S. Reshoring Accelerates
Published on 10/29/2026 at 13:00, 8 hours 15 minutes ago NuRAN Wireless Secures US$10 Million Non-Dilutive Facility and Confirms No ATM Sales at Current Market Levels
Published on 10/29/2026 at 13:00, 8 hours 15 minutes ago Core Silver Unveils Multiple New Broad Copper-Bearing VMS Intercepts at the Touleary Discovery Zone
Published on 10/29/2026 at 20:13, 1 hour 2 minutes ago Interim individual financial statements of Sirma Group JSC for the period ending on September 30, 2026
Published on 10/29/2026 at 20:07, 1 hour 8 minutes ago EQS-Adhoc: Instone Real Estate Group SE: Forecast lowered due to deterioration in the transaction environment
Published on 10/29/2026 at 19:25, 1 hour 50 minutes ago EQS-Adhoc: ProSiebenSat.1 Media SE expects a slight decline in organic revenues but reaffirms EBITDA growth outlook
Published on 10/29/2026 at 18:21, 2 hours 54 minutes ago EQS-Adhoc: Rubean AG: Rubean AG Strengthens Its Capital Base to Support Further Growth
Published on 10/29/2026 at 18:02, 3 hours 13 minutes ago TF1 9M 2026 results - Consolidated financial statements and appendix
Published on 10/29/2026 at 18:00, 3 hours 15 minutes ago GUILLEMOT CORPORATION: THIRD-QUARTER 2026 TURNOVER / Successful new product launches and acceleration of international commercial partnerships
Published on 10/29/2026 at 17:45, 3 hours 30 minutes ago ENGIE commissions 450 MW of solar capacity in India
